Syntex (u.s.a.) Inc.

Vical Incorporated

Other

Gene Therapy Systems, Inc.

Wisconsin Alumni Research Foundation

Immport Therapeutics, Inc.

University of California

Isis Pharmaceuticals, Inc.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

Rutgers, the State University of New Jersey

La Jolla Institute for Allergy and Immunology

Sanaria Inc.

Autonomous Medical Devices Inc.

Antigen Discovery, Inc.

Immport Theerapeutics, Inc.

Philip L Felgner

Jon Asher Wolff

Deborah A Eppstein

Xiaowu Liang

Dennis A Carson

Thomas Gadek

Gordon H Jones

Robert Wallace Malone

Gary H Rhodes

Richard B Roman

Maria Laura Gennaro

David J Duke

David Huw Davies

C Frank Bennett

Alan G Barbour

Raj Kumar

Xiang Gao

Channa Basava

Suezanne E Parker

Marston Manthorpe

Jukka Hartikka

Jing Ling

Richard C Border

Jiin-Yu Hwang-Felgner

Holly Horton

Olivier Zelphati

Edwin F Ullman

Ian Gibbons

Abraham Phillip Lee

William A Lee

Stephen L Hoffman

Anthony C Allison

John J Nestor, Jr

Josh Shachar

Marc Madou

Armando R Tovar

Robert Seder

Teresa H Ho

Shane Crotty

Deborah M Lidgate

Denise L Doolan

Noelene E Byars

Shizhong Chen

Cherng-chyi Fu

Uland Liao

Joseph J Campo, Jr

Linda C Foster

Barbara P Barna

Sharad D Deodhar

Andy Teng

Dongyuan Xia

The illustrated embodiments of the invention include an automated method of assaying a viral and antibody analyte in a sample in a portable, handheld microfluidic reader having a SAW detector with a minimal mass sensitivity limitation. The automated method includes the steps of automatically performing the assay with the SAW detector with enhanced sensitivity as in Optikus I, but also includes the steps of automatically disposing a second portion of the sample on a microarray, selectively automatically probing the second portion of the sample for antibodies corresponding to the at least one selected virus using the microarray, and automatically reading the microarray using a fluorescent camera to identify antibodies in the second portion of the sample.

Automated, cloud-based, point-of-care (POC) pathogen and antibody array detection system and method

Contemplated microfluidic devices and methods are drawn to protein arrays in which distinct and detergent-containing antigen preparations are deposited onto an optical contrast layer in a non-specific and non-covalent manner. Detection of binding a is carried out using a dye that precipitates or agglomerates to so form a visually detectable signal at a dynamic range of at least three orders of magnitude.

Microfluidic devices and methods

Disclosed herein are diagnostic methods and compositions for identifying individuals that are protected againstcaused malaria. Such methods are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. Also disclosed herein are subunit vaccines comprising at least one Pf immunologic determinant for protection against-caused malaria.

Serum antibody assay for determining protection from malaria, and pre-erythrocytic subunit vaccines

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (, human Herpes virus 1 and 2,, and) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

Compositions and methods for immunodominant antigens

Contemplated compositions, devices, and methods are drawn to various antigens from the pathogenand their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.

[object Object]

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (, human Herpes virus 1 and 2,, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

The present invention provides methods of detectingspecies in a sample (e.g., a sample from a patient suspected of being infected). In particular, the present invention provides compositions and methods for detecting the presence ofproteins, nucleic acid sequences encoding these proteins, and subject antibodies to these proteins, where the proteins are selected from those listed in Table 3, including: BB0279 (FLiL), BBK19, BBK07, BB0286 (FlbB), BBG33, BBL27, BBN34, BBP34, BBQ42, BBQ34, BBM34, BBN27, and BBH13.

Compositions and methods of detectingproteins, nucleic acid sequences encoding these proteins, and subject antibodies to these proteins in a sample are disclosed.

The present invention provides a pharmaceutical composition, comprising a non-infectious, non-integrating polynucleotide construct comprising a polynucleotide encoding an interferon &#x3c9; and one or more cationic compounds. The present invention also provides methods of treating cancer in a mammal, comprising administering into a tissue of the mammal a non-infectious, non-integrating polynucleotide construct comprising a polynucleotide encoding a cytokine. In addition, the present invention also relates to the methodology for selective transfection of malignant cells with polynucleotides expressing therapeutic or prophylactic molecules in intra-cavity tumor bearing mammals. More specifically, the present invention provides a methodology for the suppression of an intra-cavity dissemination of malignant cells, such as intraperitoneal dissemination. Furthermore, the invention relates to compositions and methods to deliver polynucleotides encoding polypeptides to vertebrate cells in vivo, where the composition comprises an aqueous solution of sodium phosphate.

Methods for treating cancer using interferon-&#x3c9;-expressing polynucleotides

The invention relates to, among other things, methods of protecting against poxvirus infection or pathogenesis and including pox viruses such as small pox (variola major and variola minor), cowpox, monkey pox vaccinia virus, and Molluscum Contagiosum using compositions such as human, humanized and chimeric antibodies that specifically bind to H3L protein.

H3L envelope protein immunization methods and H3L envelope passive protection methods

Growing community of inventors

Rancho Santa Fe, CA, United States of America

Philip L Felgner